Skip to main content Skip to footer

About
Services
Store
Contact
Blog
The V Clinic
Book

About
Services
Store
Contact
Blog
The V Clinic
Book

Supplements

The Gut Co – Repair
Add to basket
The Gut Co-Repair
$95.00
The Gut Co-Repair quantity
Add to basket
The Gut Co – Feed
$85.00
The Gut Co - Feed quantity
Add to basket

Filter products

Search

Search content

Product price

Product Price

Sort

Sort content

Quick links

What We Do
Clinical Grade Skin Care Products
About Us
Contact Us

Policy Information

Booking & Cancellation Policy
Shipping and Returns Policy
Privacy Policy

Booking By Appointment Only

Call us on 021 220 8850 Email us on [email protected]Our Address Office 8, The Estuary
21-23 Humphreys Drive,
Ferrymead, Christchurch 8081

Follow us on Facebook Follow us on Instagram

© 2025 Louise Highet. All rights reserved.

Built with ❤️ by Avoca Web Design in Aotearoa.

Privacy Policy Sitemap

Disclaimer

TAPS Approval No: PP2968
Advertisement Title: Louise Highet Aesthetics Website
Client: Louise Highet Aesthetics
Product: Website
This Advertisement is approved in accordance with TAPS Guidelines and Procedures. Please also see (over) the
accompanying terms and conditions of the TAPS service.
Adjudicator Signature: Peter Pratt
Approval Issue Date: 15 August 2024

According to the Medicines Act 1981 and the NZ Advertising Standards Authority, any organization promoting the use of Botox®, Xeomin®, Dysport®, Profhilo® Radiesse® are required to display the following mandatories.

Botox® is a prescription medicine for the treatment of frown lines , horizontal forehead lines and crow’s feet round the eyes and excessive sweating under the arms. Botox® has risks and benefits. Ask your specialist if Botox is right for you. If you have side effects see your doctor. You will need to pay for Botox® and clinic fees will apply. For details on precautions & side effects consult your healthcare professional or the Consumer Medicine Information (CMI) at www.medsafe.govt.nz . Botox® treatment lasts about 4 months and further courses of treatment may be necessary. (contains botulinum toxin A 50,100 & 200 units) Abbvie Ltd, Wellington.

Xeomin® is a Prescription Medicine containing 50, 100 units of incobotulinum Type A, purified Botulinum toxin type A complex for injection. It is used for the treatment of frown lines on the forehead, lateral periorbital lines and horizontal forehead lines in adults. It should be administered only by trained medical professionals. Talk to your specialist about the benefits/risks of this procedure in appearance medicine. Xeomin treatment lasts about four months and further courses of treatment may be necessary. Cautions: people receiving blood thinning medicines, care at the proposed injection sites, pregnancy and lactation. Possible side effects: headache, pain, swelling or infection at injection site, local muscle weakness including drooping eye lids, lack of feeling & nausea. You will need to pay for this medicine. Discuss with your specialist if Xeomin is right for you.

For more information or for a copy of CMI please contact the NZ distributor: NZMS Ltd: 2a Fisher Crescent, Mt Wellington, Auckland, Ph 09 259 4062.

DYSPORT® (Clostridium botulinum type A toxin-haemagglutinin complex, 500 IPSEN units) is a Prescription Medicine for the treatment of vertical frown lines between the eyebrows, and excessive underarm sweating. It should be administered only by trained medical professionals. DYSPORT® has risks and benefits. For more information, talk to your healthcare professional or read the Consumer Medicine Information available at www.medsafe.govt.nz. Ask your specialist if DYSPORT® is right for you. Always follow your specialist’s instructions. If you experience side effects and they concern you, see your healthcare professional. You will need to pay for DYSPORT® and for the administration and consultation charges. Galderma c/o Healthcare Logistics 58 Richard Pearse Drive Airport Oaks, Auckland, New Zealand.

BELKYRA® injection (deoxycholic acid 10 mg/mL) is a Prescription Medicine used for the improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. It should be administered only by trained medical professionals. BELKYRA® has risks and benefits. For more information, talk to your healthcare professional or read the Consumer Medicine Information available at www.medsafe.govt.nz. Ask your specialist if BELKYRA® is right for you. Always follow your specialist’s instructions. If you experience side effects and they concern you, see your healthcare professional. You will need to pay for BELKYRA®. Normal Doctors visit fees apply. BELKYRA® treatment should be administered only by trained medical professionals. Speak to your specialist about your own situation and about the benefits/risks of this procedure in appearance medicine.. Note: Results from BELKYRA® treatment usually last up to four years.

BELKYRA® and its design are trademarks of Kythera Biopharmaceuticals, Inc., an Allergan affiliate. ™Trademark of Allergan, Inc. Allergan Australia Pty Ltd, 810 Pacific Highway, Gordon NSW 2072. ABN 85 000 612 831. Allergan New Zealand Limited, Auckland. © 2018 Allergan.

Radiesse® (+) Lidocaine injectable implant is intended for plastic and reconstructive surgery, including deep dermal and sub-dermal soft tissue augmentation of the facial area and dorsum of the hands in adults. Radiesse® (+) Lidocaine injectable implant is indicated for: the treatment of nasolabial folds, marionette lines and jawline; the augmentation of cheeks; hand augmentation to correct volume loss in the dorsum of the hands; the restoration and/or correction of the signs of fat or volume loss (lipoatrophy) in the facial area and for rejuvenation of the hands fat loss (lipoatrophy) in people with human immunodeficiency virus. Radiesse® (+) Lidocaine should not be used on patients: with known hypersensitivity to any of the components or severe allergies including history of anaphylaxis; prone to inflammatory skin conditions, hypertrophic scars/keloids or poor wound healing; with bleeding disorders or inflamed/infected skin; in the presence of foreign bodies/implants; in the epidermis, glabellar or nose; taking anti-coagulants; in pregnancy or lactation; others. Please review the Radiesse® (+) Lidocaine Instructions for Use before prescribing for full safety information. These are available from Merz Australia on 1800 268 820or https://merzaustra lia.com.au/products/ This medical device must be administered by a Healthcare Professional. For information about how Merz handle personal data, please see Merz General Data Protection Information Notice at www.merz.com/fin Copyright ©2023. Merz Australia Pty Ltd. All rights reserved. Radiesse® and Merz Aesthetics® are registered trademarks of Merz Pharma GMbH & Co. KGaA. New Zealand: Pharmacy Retailing NZ Limited t/a Healthcare Logistics (HCL). 58 Richard Pearse Drive, Mangere, Auckland 2022. For more information please phone 0800 822 310

TEOSYAL SA, TEOSYAL RHA® 1, TEOSYAL RHA® 2, TEOSYAL RHA® 3, TEOSYAL RHA® 4, TEOSYAL® PURESENSE REDENSITY 1, TEOSYAL® PURESENSE REDENSITY 2, TEOSYAL PURESENSE KISS ®, TEOSYAL® PURESENSE GLOBAL ACTION, TEOSYAL® PURESENSE DEEP LINES, TEOSYAL® PURESENSE ULTIMATE and TEOSYAL® PURESENSE ULTRA DEEP are trademark of the firm TEOXANE SA. These products are gel that contains hyaluronic acid, and 0.3% by weight of lidocaine hydrochloride (local anesthetic can induce a positive reaction to anti-doping tests). In the case of known hypersensitivity to lidocaine and/or amide local anaesthetic agents, we recommend not use lidocaine-containing products and please refer to products without lidocaine. They are class III medical device and are regulated health product bearing the CE marking (CE2797) under this regulation. Local manifestations: inflammatory reactions (erythema, oedema, pain at the point of injection), haematomas, itching, temporary loss of sensitivity around the injected area, dyschromia, abscesses, indurations, nodules (possibly granulomas). General manifestations: immediate hypersensitivity up to anaphylactic shock, migration of the implant.

Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment or blindness,skin necrosis and stroke. Please consult your physician or pharmacist for more information.

BELOTERO® Revive is an injectable Class III medical device intended to treat early signs of photodamaged skin via rehydration of dry and very dry skin and smoothening of superficial fine lines. BELOTERO® Revive has benefits & risks. Ask your healthcare professional if BELOTERO® Revive is right for you and to explain side effects. Precautions: Bleeding disorders, keloid scars, general infection, autoimmune disease. Tell your specialist if you have side effects. Use strictly as directed. This medical device must be administered by a healthcare professional. For further information please phone 0800 822 310. Unfunded in NZ. Merz Australia. Distributed by Healthcare Logistics, Auckland. TAPS MR10377. May 2024.

Juvederm Ultra™ & Juvederm Ultra Plus™ are medical devices Class III for the filling of medium size and deep facial wrinkles by injection into the skin and for creating definition and volume in the lips. Contains 24mg/mL. cross-linked hyaluronic acid. Juvederm has risks and benefits. This medical device must be administered by a healthcare professional. Cautions: Use in an area that has been treated with another dermal filler, people with autoimmune disease, or who are pregnant, breastfeeding, under 18 years of age or have an increased susceptibility to keloid formation and hypertrophic scarring. People on blood thinning medicines. Possible side effects: injection site inflammatory reactions (redness/swelling, itching/pain on pressure) induration or nodules; discolouration; weak filling effect. If you have side effects or concerns speak to your doctor. Product and treatment costs will apply. Note: Juvederm treatment lasts about 12-24 months. For product information check with your doctor or product information at Allergan (NZ) Limited, Auckland.

Sunekos 1200 is an implantable medical device that modifies the structure of mature skin, restoring volume, filling wrinkles and folds in the skin and in scar sites. It is suitable for creating a temporary increase in the volume of skin tissue. Sunekos 1200 is a medical device that is sterile, injectable, non-pyrogenic, biocompatible, reabsorbable, made with hyaluronic acid and amino acids. Sunekos Performa is a medical device recommended for the treatment of blemishes and depressions in the skin caused by wrinkles and scars. Sunekos Performa is a sterile resorbable injectable solution which acts as a filler, supporting the restoration of physiological elasticity and temporarily replacing volume by expanding the soft tissues. Sunekos should not be used on patients: with known hypersensitivity to any of its components; presenting with a general infection, inflammatory or infectious cutaneous problems; with history of severe multiple allergies or anaphylactic shock; prone to hypertrophic scars/keloids or streptococcal diseases; in patients presenting with porphyria; under 18 years of age; in pregnancy or lactation; others. See full Instructions for use before prescribing for full safety information, available from www.xytide.co.nz Copyright© 2024. Xytide Biotech Pty Ltd. Always read the label and follow the instructions. This medical device must be administered by a Healthcare Professional. New Zealand Sponsor: AA-Med Pty Ltd Distributed by: Xytide Biotech NZ Pty Ltd (NZBN 9429049668612) C/O Alliott Ltd, Level 2, 142 Broadway, Newmarket, Auckland 1023 NZ. For more information please phone +61 1800 570 036.

REJURAN is a dermal tissue reconstructive material, animal-derived. REJURAN is an injectable gel which is intended for injection into the mid to deep dermis to promote tissue restoration and reconstruction, and improvement of physical appearance.

Administered by injecting the gel into the dermis using a thin gauge needle. The polynucleotide is hydrating to cause volumetric increases of tissues and make more favourable physiological conditions for the growth of cells in the skin.

REJURAN treatment is not funded on the New Zealand Pharmaceutical Schedule. You will need to pay for this medicine. Normal Doctors visit fees apply. REJURAN treatment should be administered only by trained medical professionals. Speak to your doctor about your own situation and about the benefits/risks of this procedure in appearance medicine. For further information, the Data Sheet and Consumer Medicines